Beam Therapeutics Inc. BEAM
Beam Therapeutics Inc. (Nasdaq: BEAM) is a hematology drug developer. Its lead program, risto-cel, is in Phase 3 for sickle cell disease. Its next catalyst on record is risto-cel: Updated data from BEACON trial (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: risto-cel — Updated data from BEACON trial (2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| risto-cel | sickle cell disease | ex vivo base editing | Phase 3 |
| BEAM-302 | alpha-1 antitrypsin deficiency (AATD) | in vivo LNP base editing | Phase 2 |
| BEAM-301 | glycogen storage disease Ia (GSDIa) | in vivo LNP base editing | Phase 2 |
| BEAM-304 | phenylketonuria (PKU) | in vivo LNP base editing | Phase 1 |
| BEAM-103 | anti-CD117 antibody for ESCAPE platform | antibody | Phase 1 |
| In vivo HSC-targeted LNP | sickle cell disease | in vivo LNP base editing | Pre-clinical |
Recent results and decisions
- Nov 3, 2026n/a U.S. BLA submission for risto-cel in sickle cell disease expected as early as year-end 2026.
Beam expects to report updated clinical data by year-end 2026 and submit a U.S. biologics license application (BLA) for risto-cel as early as year-end 2026.
Filing - Nov 3, 2026n/a Dosing in Phase 1/2 trial of BEAM-304 in PKU anticipated to initiate in early 2027.
Beam expects to initiate dosing in the Phase 1/2 trial in early 2027.
Filing - Oct 31, 2026positive Initial BEAM-301 data showed dose-dependent improvements in time to fasting hypoglycemia with two of three patients in the 40 mg cohort achieving maximum controlled fasting duration of ≥15 hours and complete elimination of starch supplementation.
Initial BEAM-301 clinical data demonstrated dose-dependent improvements in time to fasting hypoglycemia (TTH) across all patients, with two of three patients in the 40 mg cohort achieving the protocol-defined maximum controlled fasting duration of ≥15 hours, consistent with restored endogenous gluco
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.